10.3389/fimmu.2019.00547.s003 Ming Ni Ming Ni Lei Wang Lei Wang Mingya Yang Mingya Yang Brigitte Neuber Brigitte Neuber Leopold Sellner Leopold Sellner Angela Hückelhoven-Krauss Angela Hückelhoven-Krauss Maria-Luisa Schubert Maria-Luisa Schubert Thomas Luft Thomas Luft Ute Hegenbart Ute Hegenbart Stefan Schönland Stefan Schönland Patrick Wuchter Patrick Wuchter Bao-an Chen Bao-an Chen Volker Eckstein Volker Eckstein William Krüger William Krüger Ronit Yerushalmi Ronit Yerushalmi Katia Beider Katia Beider Arnon Nagler Arnon Nagler Carsten Müller-Tidow Carsten Müller-Tidow Peter Dreger Peter Dreger Michael Schmitt Michael Schmitt Anita Schmitt Anita Schmitt Table_1_Shaping of CD56bri Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis.docx Frontiers 2019 GvHD ECP immunomodulation natural killer cells anti-viral effect anti-leukemia effect 2019-03-20 12:58:23 Dataset https://frontiersin.figshare.com/articles/dataset/Table_1_Shaping_of_CD56bri_Natural_Killer_Cells_in_Patients_With_Steroid-Refractory_Resistant_Acute_Graft-vs_-Host_Disease_via_Extracorporeal_Photopheresis_docx/7868345 <p>CD56<sup>bri</sup> natural killer (NK) cells play an important role in the pathogenesis of graft-vs. -host disease (GVHD) and immune defense in the early period after allogeneic hematopoietic stem cell transplantation. Extracorporeal photopheresis (ECP) as an immunomodulating therapy has been widely used for GVHD treatment. However, the mechanism of action of ECP still remains to be elucidated, particularly the influence of ECP on NK cells. Thirty-four patients with steroid-refractory/resistant acute GVHD (aGVHD) ≥ °II and moderate to severe chronic GVHD (cGVHD) received ECP therapy. Patient samples obtained during intensive and long-term treatment were analyzed. Immunomonitoring with respect to cell phenotype and function was performed on rested peripheral blood mononuclear cells (PBMCs) using multiparametric flow cytometry. NK activity in terms of cytokine release was analyzed by intracellular cytokine staining after co-culture with K562 cells. Moreover, the proliferative capacity of NK cells, CD4<sup>+</sup>, and CD8<sup>+</sup> T cells was determined by carboxyfluorescein succinimidyl ester (CFSE) staining. Clinically, 75% of aGVHD and 78% of cGVHD patients responded to ECP therapy. Moreover, our data show that aGVHD, cGVHD patients and healthy donors (HDs) present distinct NK patterns: aGVHD patients have a higher frequency of CD56<sup>bri</sup> NK subsets with stronger NKG2D and CD62L expression, while CD56<sup>−</sup>CD16<sup>+</sup> NK cells with higher expression of CD57 and CD11b stand out as a signature population for cGVHD. ECP therapy could significantly decrease CD56<sup>bri</sup>CD16<sup>−</sup> NK cells with shifting the quality from a cytotoxic to a regulatory pattern and additionally mature CD56<sup>dim</sup> NK cells via upregulation of CD57 in complete responding aGVHD patients. Moreover, ECP could keep the anti-viral and anti-leukemic effects intact via maintaining specialized anti-viral/leukemic CD57<sup>+</sup>NKG2C<sup>+</sup>CD56<sup>dim</sup> NK cells as well as remaining the quality and quantity of cytokine release by NK cells. The proliferative capacity of effector cells remained constant over ECP therapy. In conclusion, ECP represents an attractive option to treat GVHD without compromising anti-viral/leukemic effects. Shaping of CD56<sup>bri</sup> NK cell compartment by downregulating the cytotoxic subset while upregulating the regulatory subset contributes to the mechanisms of ECP therapy in aGVHD.</p>